ATX inhibitor 18

Cat. No.:	HY-146205
CAS No.:	2402772-30-7
Molecular Formula:	$C_{21}H_{17}Cl_2FN_6O$
Molecular Weight:	459.3
Target:	Phosphodiesterase (PDE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ATX inhibitor 18 is a potent ATX inhibitor with an IC_{50} value of 24.2 nM. ATX inhibitor 18 shows antiproliferative activity and anti-fibrosis activity. ATX inhibitor 18 suppresses collagen deposition in TGF-β-mediated cardiac fibrosis[1].
IC_{50} & Target	Autotaxin 24.2 nM (IC_{50})
In Vitro	ATX inhibitor 18 (compound 8b) (10 μM; 48 h) shows antiproliferative activity in CFs, t-HSC/Cl-6 cells[1]. ATX inhibitor 18 (0-4 μM) shows anti-fibrosis activity with IC_{50}s of 0.87 and 1.10 μM for CFs, t-HSC/Cl-6 cells, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assaysup>[1]

Cell Line:	CFs, t-HSC/Cl-6 cells
Concentration:	10 μM
Incubation Time:	48 h
Result:	Showed antiproliferative activity with inhibitory activity of 81.5% and 79.4% for CFs, t-HSC/Cl-6 cells, respectively.

REFERENCES

[1]. Jiang N, et al. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis. Eur J Med Chem. 2020 Feb 1;187:111904.

[2]. Jiang N, et al. Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis. Eur J Med Chem. 2020 Feb 1;187:111904.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA